 The FDA has issued a Complete Response Letter to BeyondSpring Pharmaceuticals Incs NASDAQ: BYSI marketing application seeking approval for plinabulin to prevent chemotherapy-induced neutropenia CIN. The application covers plinabulin in combination with granulocyte colony-stimulating factor G-CSF. 